Research programme: endothelial dysfunction therapeutics - Antibe Therapeutics

Drug Profile

Research programme: endothelial dysfunction therapeutics - Antibe Therapeutics

Alternative Names: ATB-901

Latest Information Update: 08 Jul 2011

Price : $50

At a glance

  • Originator Antibe Therapeutics
  • Class
  • Mechanism of Action Antioxidants; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Erectile dysfunction; Vascular disorders

Most Recent Events

  • 08 Jul 2011 Discontinued - Preclinical for Erectile dysfunction in United Kingdom (unspecified route)
  • 08 Jul 2011 Discontinued - Preclinical for Vascular disorders in Canada (unspecified route)
  • 01 Feb 2007 No development reported - Preclinical for Erectile dysfunction in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top